PLEASANTON, Calif.,
Jan. 4, 2011 /PRNewswire/ -- Thoratec
Corporation (Nasdaq: THOR), a world leader in device-based
mechanical circulatory support therapies to save, support and
restore failing hearts, said today it will be participating in the
29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11.
Gary F. Burbach, president and
chief executive officer, will provide an update on the company,
beginning at 4:30 p.m., Pacific Standard
Time (7:30 p.m., Eastern Standard
Time).
The presentation will be available through the conference web
site at
http://jpmorgan.metameetings.com/webcasts/healthcare11/directlink?ticker=THOR,
or on the company's web site at http://www.thoratec.com.
Thoratec is a world leader in therapies to address
advanced-stage heart failure. The company's products include the
HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD
(Ventricular Assist Device) with more than 15,000 devices implanted
in patients suffering from heart failure. Thoratec is headquartered
in Pleasanton, California. For
more information, visit the company's web site at
http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are
registered trademarks of Thoratec Corporation and IVAD is a
trademark of Thoratec Corporation.
SOURCE Thoratec Corporation